Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP1001-A in Advanced Solid Tumors
NCT04196257Phase 1Recruiting
- Sponsor
- Bio-Path Holdings, Inc.
- Start
- Aug 2022
- Primary completion
- Jul 2027
- Modality
- Nanoparticles, Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of prexigebersen in solid tumor, ovarian cancer, endometrial cancer (EC) and 2 more (2 arms), sponsored by Bio-Path Holdings, Inc. Primary endpoints: Dose Limiting Toxicity at 30 days, Maximum Tolerated Dose at 30 days and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
prexigebersen
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04196257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196257.